Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $392.3 million.

  • Ocular Therapeutix's Net Cash Flow rose 121705.68% to $392.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $345.0 million, marking a year-over-year increase of 7586.89%. This contributed to the annual value of $345.0 million for FY2025, which is 7586.89% up from last year.
  • As of Q4 2025, Ocular Therapeutix's Net Cash Flow stood at $392.3 million, which was up 121705.68% from -$46.4 million recorded in Q3 2025.
  • In the past 5 years, Ocular Therapeutix's Net Cash Flow registered a high of $392.3 million during Q4 2025, and its lowest value of -$46.4 million during Q3 2025.
  • For the 5-year period, Ocular Therapeutix's Net Cash Flow averaged around $25.4 million, with its median value being -$16.3 million (2021).
  • Per our database at Business Quant, Ocular Therapeutix's Net Cash Flow plummeted by 19719.97% in 2021 and then skyrocketed by 133348.37% in 2024.
  • Over the past 5 years, Ocular Therapeutix's Net Cash Flow (Quarter) stood at -$15.1 million in 2021, then decreased by 23.37% to -$18.6 million in 2022, then skyrocketed by 557.14% to $85.3 million in 2023, then crashed by 141.19% to -$35.1 million in 2024, then surged by 1217.06% to $392.3 million in 2025.
  • Its last three reported values are $392.3 million in Q4 2025, -$46.4 million for Q3 2025, and $41.5 million during Q2 2025.